Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Targeting the Gut for Stroke Neuroprotection; IGF-1 Modulation of the Blood-Gut Barrier

Award Number: R01NS119872
ORGANIZATION: NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 05/01/2022
PERIOD OF PERFORMANCE END DATE: 04/30/2027

Group Awards By:

View Award Description

Targeting the Gut for Stroke Neuroprotection; IGF-1 Modulation of the Blood-Gut Barrier - Almost 2/3rds of stroke survivors exhibit vascular cognitive impairment and a third of stroke patients will develop dementia 1-3 years after stroke. Menopause significantly increases the risk for stroke and may underlie the greater prevalence of AD/ADRD seen in women as compared to men. Using acyclic middle-aged female rats to model the estrogen-deficient postmenopausal state, we found that ischemic stroke produced larger brain infarcts in this population as compared to normally-cycling, adult females, and that estrogen treatment, paradoxically, increased brain damage in older acyclic female rats. These data are congruent with the Women’s Health Initiative study, where the stroke risk and mortality were elevated in women who received hormone therapy and underscores the need for novel therapeutic approaches for this older demographic. Our previous work shows that the peptide hormone Insulin-like Growth Factor (IGF)-1 delivered intracerebroventricularly (icv) to acyclic middle-aged female rats after stroke, reduces infarct volume and neuroinflammation, and preserves blood brain barrier function during the acute phase. Since stroke leads to long term dementia-related symptoms such as depression and cognitive impairment, we initiated pilot studies on these outcomes. Surprisingly, icv-IGF-1 did not improve depressive behaviors when measured 30-60 days after stroke and failed to reduce serum levels of inflammatory cytokines either in the acute or chronic phase. We propose that the dichotomy between the robust neuroprotective actions of icv-IGF-1 in the acute phase, with the lack of effect on chronic stroke outcomes occurs because icv-IGF-1 is not available to target organs outside the brain that are critical for suppressing inflammation and long-term stroke recovery. In view of the evidence that the gut is home to the largest contingent of immune cells, and gut metabolites such as short chain fatty acids are critical for reducing peripheral inflammation and improving blood brain barrier integrity, we propose that improvement of long-term outcomes from stroke will require IGF-1 action on the gut intestinal barrier. The intestinal barrier is critical for containing the immune response and reducing gut dysbiosis. Here we will test the hypothesis that in contrast to icv-IGF-1, peripheral IGF-1 (ip or oral), will improve (a) acute stroke disability (2-5d) as well as depressive-like behaviors and cognitive impairment in the chronic phase (21-180d), (b) preserve the intestinal barrier, thus preventing the extravasation of activated gut immune cells and (c) ameliorate chronic pro-inflammatory changes to the gut microbiota and gut metabolites. These studies are innovative in assessing the long-term cognitive effects of stroke which are understudied in preclinical research. In addition, our focus on reproductive senescent female rats that is reflective of the aging human post-menopausal female, has unique translational relevance, since the prevalence of AD/ADRD is much higher in females. At the conclusion of these studies, we expect to have a better understanding of the role of extra neural targets in mediating post-stroke dementia.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $549,767 )
2026	2026	TEXAS A & M UNIVERSITY SYSTEM HEALTH SCIENCE CENTER	6003 TAMU	COLLEGE STATION	TX	77843	BRAZOS	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	000	3	4/17/2026	NON-COMPETING CONTINUATION	$549,767
														Subtotal = $549,767

Issue Date FY: 2025 ( Subtotal = $534,246 )
2025	2025	TEXAS A & M UNIVERSITY SYSTEM HEALTH SCIENCE CENTER	6003 TAMU	COLLEGE STATION	TX	77843	BRAZOS	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	000	2	8/9/2025	EXTENSION WITH OR WITHOUT FUNDS	$534,246
														Subtotal = $534,246

Grand Total All Awards = $1,084,013

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Targeting the Gut for Stroke Neuroprotection; IGF-1 Modulation of the Blood-Gut Barrier

Award Number: R01NS119872

ORGANIZATION: NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 05/01/2022

PERIOD OF PERFORMANCE END DATE: 04/30/2027

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer